Masimo Co. (NASDAQ:MASI) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Masimo Co. (NASDAQ:MASI) by 45.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 525,594 shares of the medical equipment provider’s stock after buying an additional 165,257 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.99% of Masimo worth $66,201,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in Masimo by 282.0% during the fourth quarter. Wells Fargo & Company MN now owns 116,712 shares of the medical equipment provider’s stock worth $13,680,000 after buying an additional 86,162 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in Masimo by 11.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 54,839 shares of the medical equipment provider’s stock valued at $8,053,000 after purchasing an additional 5,688 shares during the period. Advisors Asset Management Inc. increased its position in Masimo by 32.1% during the first quarter. Advisors Asset Management Inc. now owns 9,009 shares of the medical equipment provider’s stock worth $1,323,000 after purchasing an additional 2,187 shares during the last quarter. Vanguard Group Inc. raised its stake in Masimo by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock worth $560,421,000 after purchasing an additional 26,473 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Masimo by 33.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,196 shares of the medical equipment provider’s stock valued at $6,196,000 after purchasing an additional 10,683 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on MASI shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Friday, September 20th. Piper Sandler boosted their target price on Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $144.67.

Masimo Stock Up 0.1 %

MASI stock opened at $133.20 on Friday. The company has a market capitalization of $7.08 billion, a P/E ratio of 90.61 and a beta of 0.98. The firm has a 50 day simple moving average of $116.67 and a 200-day simple moving average of $124.97. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. Masimo Co. has a twelve month low of $75.22 and a twelve month high of $153.93.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.77 by $0.09. The firm had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. Masimo’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS. On average, equities research analysts predict that Masimo Co. will post 3.87 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.